Evaluation of patient outcomes from the kidney allograft outcomes allosure registry (KOAR),
Role: Investigator,
CareDx, Inc.,
(10/2024 - 10/2025)
Status: Approved
A phase 3 prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transplants,
Role: Investigator,
Medeor Therapeutics, Inc.,
(05/2023 - 04/2024)
Status: Completed
A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(02/2018 - 02/2019)
Status: Completed
A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015),
Role: Investigator,
Oxford Immunotec,
(07/2017 - 07/2018)
Status: Completed
Evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock (EUPHRATES),
Role: Investigator,
Spectral Diagnostics Inc.,
(07/2014 - 07/2015)
Status: Completed
A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with mycophenolate mofetil for the prevention of acute allograft rejection in De Novo adult kidney transplant recipients (protocol LCP-Tacro 3002 version 3.0 September 30, 2010),
Role: Investigator,
LifeCycle Pharma A/S,
(10/2013 - 10/2014)
Status: Completed
A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of alefacept in de novo kidney transplant recipients,
Role: Investigator,
Astellas Pharma US, Inc.,
(01/2011 - 01/2012)
Status: Completed
A phase IV, non interventional, multi-center, open-label, prospective, observational study of the safety, effectiveness, tolerability and compliance of immunosuppressive regimen using mycophenolic acid to treat de novo renal transplant patients in routine clinical practice,
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(05/2010 - 05/2011)
Status: Completed
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled certican in two doses (1.5 and 3.0 g/day starting doses) with reduced neoral versus 1.44g myfortic with standard dose neoral in de novo renal transplant recipients.,
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(10/2006 - 10/2007)
Status: Completed
Internal
Highly Suppressive Regulatory T Cell as a Biomarker for Immunologically Relevant Delayed/Slow Graft Function after Kidney Transplantation,
Role: Investigator,
LLU Dept. of Surgery,
(10/2020)
Status: Approved
Azotemia in portal hypertension and the role of endothelin-1 and nitric oxide in inducing hepatorenal syndrome and refractory ascites,
Role: Investigator,
LLU Transplantation Institute,
(10/2008 - 10/2009)
Status: Completed
Clinical outcomes of induction therapies in renal transplant patients,
Role: Investigator,
LLU Transplantation Institute,
(12/2007 - 12/2015)
Status: Completed
Incidence of Glomerular Disease Post-Kidney Transplant,
Role: Investigator,
LLU Dept. of Medicine,
(10/2024)
Status: Approved
Assessment of IVIG in highly sensitized patients with panel reactive antigen (PRA) of over 94%.,
Role: Investigator,
LLU Transplantation Institute,
(04/2025)
Status: Approved
Non-Profit Organization
Integration of donor-derived cell-free DNA with HLA-DR+TNFR2+ regulatory T cell in the prediction of acute rejection and graft function after kidney transplantation,
Role: Investigator,
American Society of Transplant Surgeons,
(08/2024 - 08/2025)
Status: Approved
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppresion Trial (BENEFIT),
Role: Investigator,
Bristol-Myers Squibb Foundation, Inc.,
(01/2010 - 01/2011)
Status: Completed